FY2025 · ended Dec 31, 2025 · Revenue $80.28M, +15.8% YoY · Filed Mar 25, 2026
TELA Bio, Inc. (TELA) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $80.3 million and a net loss of $38.8 million. Free cash flow was -$28.7 million. As of Jun 30, 2026 it held $30.4 million in cash and investments and $56.6 million in total debt.
Revenue (TTM)
$79.91M
+6.1% vs year-ago TTM
Net income (TTM)
$-41.18M
-1.0% vs year-ago TTM
Operating cash flow (TTM)
$-31.14M
+8.8% vs year-ago TTM
Free cash flow (TTM)
$-31.62M
+8.8% vs year-ago TTM
EPS (TTM)
$-0.78
+26.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
44.74M
+13.1% vs prior year
Net cash
$-26.19M
as of Jun 30, 2026
Operating margin
-42.6%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- TELA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Malvern, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1561921
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $80.3M | $69.3M | $58.5M | $41.4M | $29.5M |
| Operating income | -$33.8M | -$34.1M | -$44.1M | -$39.0M | -$29.5M |
| Net income | -$38.8M | -$37.8M | -$46.7M | -$44.3M | -$33.3M |
| Diluted EPS | -$0.83 | -$1.33 | -$2.04 | -$2.72 | -$2.30 |
| Operating cash flow | -$28.2M | -$41.6M | -$40.9M | -$40.7M | -$30.4M |
| Free cash flow | -$28.7M | -$42.6M | -$41.5M | -$41.6M | -$31.1M |
| Total assets | $81.4M | $86.6M | $78.0M | $67.9M | $62.5M |
| Total liabilities | $75.1M | $58.1M | $59.2M | $53.5M | $42.4M |
| Stockholders' equity | $6.3M | $28.5M | $18.9M | $14.3M | $20.1M |
| Cash and investments | $50.8M | $52.7M | $46.7M | $42.0M | $43.9M |
| Total debt | $57.7M | $43.1M | $42.8M | $41.5M | $31.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 8, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Other events
|
Oct 6, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Other events
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 29, 2026 | Sep 28, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 18, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Regulation FD disclosure
|
Aug 31, 2026 | Aug 28, 2026 |
All 545 TELA Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.